Actuate Therapeutics, Inc.

About Actuate Therapeutics, Inc.

Actuate Therapeutics aims to provide patients with hard-to-treat cancers the opportunity to live longer and better by developing therapies with the potential to slow, stop, or shrink tumors with minimal adverse effects. Their lead drug, elraglusib, is a novel GSK-3 inhibitor targeting multiple molecular pathways in cancer.

Products & Services

Elraglusib:A novel GSK-3 inhibitor targeting multiple molecular pathways in cancer to promote tumor growth inhibition and resistance to conventional cancer drugs. It also mediates anti-tumor immunity by inhibiting immune checkpoints and regulating immune cell function.

Pipeline Therapies:Additional therapies and potential indications are under development for various hard-to-treat cancers.

Specialties

Hard-to-treat cancers GSK-3 inhibitors Anti-tumor immunity Molecular pathways in cancer

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 17250000 MR: - FA: 17.25 million FAN: 17250000	D: 2025-09-11 FD: 2025-09-11	2 investors
2	RT: Public Offering T: - FT: Public Offering	A: 15000000 MR: - FA: 15.0 million FAN: 15000000	D: 2025-09-10 FD: 2025-09-10	2 investors
3	RT: Initial Public Offering T: - FT: Initial Public Offering	A: 22400000 MR: - FA: $22,400,000 FAN: 22400000	D: 2024-08-14 FD: 2024-08-14	2 investors
4	RT: IPO T: - FT: IPO	A: 22400000 MR: - FA: 22,400,000 FAN: 22400000	D: 2024-08-12 FD: 2024-08-12	2 investors

Public Offering Latest

2025-09-11

$17.2M

2 investors (Pro only)

Public Offering 2025-09-10

$15.0M

Initial Public Offering 2024-08-14

$22.4M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Daniel M. Schmitt

President & Chief Executive Officer

A

Andrew P. Mazar, Ph.D.

Chief Operating Officer

P

Paul Lytle

Chief Financial Officer

S

Susan Gallipoli, RN, MSN

Senior Director, Pharmacovigilance

C

Carrie Kellinger

Senior Director, Operations

R

Richard Kenley, Ph.D.

Vice President, Chemistry, Manufacturing, & Controls

View 31 more team members with Pro

Unlock Full Team Directory

Recent News